$因塞特(INCY)$ Incyte/Merck cancer collaboration now includes seven late-stage studies。 The previously announced collaboration between Incyte (NASDAQ:INCY) and Merck (NYSE:MRK) evaluating the combination of epacadostat and KEYTRUDA (pembrolizumab) in five tumor types now includes seven Phase 3 studies: one in melanoma, two in non-small cell lung cancer, two in bladder cancer, one in kidney cancer and one in head and neck cancer.